Navigation Links
Novartis to Expand Global Research Headquarters in Cambridge, MA
Date:10/27/2010

CAMBRIDGE, Mass., Oct. 27 /PRNewswire/ -- Novartis announced today that it will add 300 new jobs and invest $600 million over the next five years to expand its global Research headquarters campus on Massachusetts Avenue in Cambridge, Mass.  

"Novartis was the first global pharmaceutical company to move its Research headquarters to Massachusetts just a few years ago.  It has achieved prominence and, we believe, helped to amplify Cambridge's magnetism for others in the biomedical field to follow," said Mark Fishman, President of the Novartis Institutes for BioMedical Research.  "Our scientists and physicians here already have discovered a host of new medicines, and established fruitful collaborations with academic, clinical, and biotech institutions.  The constellation of talent and environment are unmatched.  We look forward to the next wave of new medicines coming from this center."

The company plans to expand its current Massachusetts Avenue campus, adjacent to MIT, by more than 400,000 square feet, including laboratory, office and retail space. Construction is expected to begin in 2011.

"Novartis' commitment to expand and create more jobs in Massachusetts is an affirmation of the Commonwealth's international leadership and investments in the life sciences," said Governor Deval Patrick. "As one of the key drivers of our innovation economy, Novartis' new plan to create jobs and invest in Massachusetts offers proof that businesses are growing here and our economy is on the move."

The new campus will be built on a four-acre parcel that Novartis is leasing from MIT under an expanded agreement originally signed in 2009.

"Novartis is a life sciences leader and exemplary corporate citizen in Cambridge," said Cambridge Mayor David Maher. "This is a global company that acts locally through a wide variety of programs in our community.  Their decision to grow here is great news for Cambridge and a testament
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  InnoPharma, Inc. today announced the ... generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is ... behaviors in patients with schizophrenia or bipolar I mania. ... drug, InnoPharma has entered into an agreement with Sandoz ... will make, use, sell, market and distribute Olanzapine Injection ...
(Date:7/30/2014)... and PARIS , July 30, ... ) and Sanofi (EURONEXT: SAN and NYSE: ... ODYSSEY trials of alirocumab in people with hypercholesterolemia met ... from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 ... an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 ... products for oncology supportive care, announced that its novel ... featured in an article on OncLive.com titled, "Study Finds ... Neck Cancers."  Dr. Steve Sonis , a leading ... demand seen in the oncology community for evidence-based strategies ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... /PRNewswire-Asia-FirstCall/ -- Golden Meditech Holdings ("Golden Meditech," 0801.HK, ... Bon International") today announced that the companies have ... strategic cooperation in Taipei.  Golden Meditech Holdings Chairman, ... International, Mr. Chu Powei, respectively represented and co-chaired ...
... BRUNSWICK, N.J., and LEIDEN, Netherlands, Feb. 17, 2011 ... (NYSE Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) today ... to acquire Crucell N.V. (Crucell) has been satisfied.  The initial offering ... a.m. New York time) on 16 February 2011.   ...
Cached Medicine Technology:Golden Meditech to Form Strategic Alliance with Long Bon International 2Golden Meditech to Form Strategic Alliance with Long Bon International 3Minimum Acceptance Condition Satisfied 2Minimum Acceptance Condition Satisfied 3Minimum Acceptance Condition Satisfied 4Minimum Acceptance Condition Satisfied 5Minimum Acceptance Condition Satisfied 6
(Date:7/31/2014)... 31, 2014 USHIO America’s Solid ... and general lighting marketplaces, today announced the launch ... will allow users to transform existing, inefficient lamp-based ... minutes. , USHIO America’s Uphoria LED downlight retrofit ... cans, allowing the user to upgrade old incandescent ...
(Date:7/31/2014)... Palm Coast Florida (PRWEB) July 31, 2014 ... the agenda for the upcoming inaugural Clinical Issues ... to be held October 13-17, 2014 at the Wailea ... " This incredible agenda has been developed for ... many of the critical CME topics," says Barbara Lyons, ...
(Date:7/31/2014)... 2014 The study, The Truth ... Medicare episode of care payments for four clinical areas—congestive ... joint replacements (hips and knees). Using the definition ... for Care Improvement program, the study examines these clinical ... in the country. , “Our study reaffirms that, in ...
(Date:7/30/2014)... Push to Walk and Macy’s invite customers ... A Cause” charity shopping event on August 23, 2014. ... shopping event created to support local charities’ fundraising efforts, ... charities across the country since 2006. Customers can participate ... Push to Walk now. , “Macy’s is ...
(Date:7/30/2014)... 31, 2014 CareSource, a nonprofit, Ohio-based ... President and CEO, Wright-Patt Credit Union, to the CareSource ... foremost financial CEO with an extensive background in leading ... and later chief operating officer at Wright-Patt Credit Union ... the Beavercreek-based Wright-Patt Credit Union that has realized more ...
Breaking Medicine News(10 mins):Health News:USHIO America Introduces Uphoria™ LED Downlight Retrofit Kits 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 2Health News:Push to Walk Participates in Macy’s Ninth Annual “Shop For A Cause” 3
... , , , , ... Pioneering Innovation Award today at the Centers for Disease Control and ... These organizations are being recognized for their work in advancing policies ... With rising rates of obesity in adults, particularly those ...
... ... consumers to be aware of non-approved cosmetic injections , ... (PRWEB) July 29, 2009 -- The Physicians Coalition ... products, touting everything from cellulite treatment to weight loss are not FDA approved, and ...
... CLEARWATER, Fla., July 29 BayCare Health System today announced ... To Work For by Florida Trend magazine . ... medium and large companies, were compiled from surveys of participating companies, employees ... the August issue of Florida Trend and on FloridaTrend.com. , ...
... , NEW ORLEANS, July 29 ... showing its pioneering spirit again by leading the way to making healthy ... , , Consumers in Tokyo will be the ... with the first store planned to open in 2010. Japan makes sense ...
... EMERYVILLE, Calif., July 29 Bionovo, Inc. (Nasdaq: ... the unmet needs in women,s health and oncology, today announced that ... Senior Vice President and CFO, will be presenting at the BMO ... EDT on Wednesday, August 5, 2009. The event will be held ...
... day cut risk in half in study of Finnish men ... associated with moderate- to high-intensity exercise appears to reduce the ... Finnish study included 2,560 men, aged 42 to 61, whose ... the men had a history of cancer, according to the ...
Cached Medicine News:Health News:CDC Recognizes Innovative Obesity Prevention and Control Initiatives With Weight of the Nation Awards 2Health News:CDC Recognizes Innovative Obesity Prevention and Control Initiatives With Weight of the Nation Awards 3Health News:CDC Recognizes Innovative Obesity Prevention and Control Initiatives With Weight of the Nation Awards 4Health News:Carboxytherapy and Mesotherapy Unproven, Warns The Physicians Coalition for Injectable Safety 2Health News:Carboxytherapy and Mesotherapy Unproven, Warns The Physicians Coalition for Injectable Safety 3Health News:BayCare Named to Top 100 Best Companies To Work For in Florida by Florida Trend Magazine 2Health News:BayCare Named to Top 100 Best Companies To Work For in Florida by Florida Trend Magazine 3Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 2Health News:Smoothie King Expansion Signals International Trend Toward Healthy Living 3Health News:Bionovo to Present at the BMO Capital Markets Ninth Annual Focus on Healthcare Conference 2
A new flexible endoscope with an ultra dense optic fiber system. Its two working and irrigation channels and steering mechanism makes it ideal for a multipurpose use in neurosurgical endoscopy i.e. V...
... Performance Instrument System. It is the only ... electric power with the unparalleled high performance ... The advanced design of this instrument system ... cooling system, advanced control circuitry, and the ...
The XK-PRO 100 High Speed Drill System is a compact, lightweight design that offers new technological and performance standards for a combination of surgical procedures....
... The Legend Platinum is a compact ... 77,000 rpm at 120 psi/8 bar, ... of comparable size with noticeable noise ... design combines with an enhanced ergonomic ...
Medicine Products: